ArticleScientific reports2018
The action of a negative allosteric modulator at the dopamine D
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Design, Synthesis, and Characterization of Novel, Subtype-Selective Fluorescent Antagonists Targeting the Nociceptin/Orphanin FQ Opioid Peptide Receptor.Journal of medicinal chemistry · 2026Article
- Allosteric Modulators of Dopamine DMolecules (Basel, Switzerland) · 2022Review
- The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects.Biophysical chemistry · 2022Review
- In Search of Synergistic Insect Repellents: Modeling of Muscarinic GPCR Interactions with Classical and Bitopic Photoactive Ligands.Molecules (Basel, Switzerland) · 2022Article
- Allosteric modulation of dopamine DPharmacological reports : PR · 2022Article
- Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine DBiomedicines · 2021Article
- Novel Dual-Target μ-Opioid Receptor and Dopamine DJournal of medicinal chemistry · 2021Article
- Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the DACS chemical neuroscience · 2020Article
- Enhancing the Signaling of GPCRs via Orthosteric Ions.ACS central science · 2020Article
- Residues and residue pairs of evolutionary importance differentially direct signaling bias of D2 dopamine receptors.The Journal of biological chemistry · 2019Article
- Harnessing Ion-Binding Sites for GPCR Pharmacology.Pharmacological reviews · 2019Review
- cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology-tribute to Karl H. Jakobs.Naunyn-Schmiedeberg's archives of pharmacology · 2019Review
- The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as DJournal of medicinal chemistry · 2019Article
- Allostery in G protein-coupled receptors investigated by molecular dynamics simulations.Current opinion in structural biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Christopher J Draper-JoyceDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Ravi Kumar VermaComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland, 21224, United States.
Mayako MichinoComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland, 21224, United States.
Jeremy ShonbergMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Anitha KopinathanMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Carmen Klein HerenbrinkDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Peter J ScammellsMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Ben CapuanoMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Ara M AbramyanComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland, 21224, United States.
David M ThalDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Jonathan A JavitchDepartments of Psychiatry and Pharmacology, New York State Psychiatric Institute, New York, New York, 10032, United States.
Arthur ChristopoulosDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia.
Lei ShiComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland, 21224, United States. lei.shi2@nih.gov.
J Robert LaneDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, VIC 3052, Australia. rob.lane@monash.edu.ORCID http://orcid.org/0000-0002-7361-7875
Monash University · AUNational Institutes of Health · USDiscovery Institute · USNew York Psychoanalytic Society and Institute · US
Funding
Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptorZIADA000606 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHI, LEI · 2015 to 2025
$20.5MAbstract
Sodium ions (Na
Indexed as
Allosteric RegulationAnimalsBinding SitesCHO CellsCricetulusDopamineDopamine D2 Receptor AntagonistsHumansIndolesIonsIsoquinolinesKineticsMolecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationMolecular Structure1H-indole-2-carboxylic acid (4-(2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl)cyclohexyl)amideDopamineDopamine D2 Receptor AntagonistsIndolesIonsIsoquinolinesReceptors, Dopamine D2Sodium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.